Kidney Dosimetry in177Lu and90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kidney Dosimetry in177Lu and90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
Authors
Keywords
-
Journal
Biomed Research International
Volume 2013, Issue -, Pages 1-12
Publisher
Hindawi Limited
Online
2013-06-21
DOI
10.1155/2013/935351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy
- (2012) Sébastien Baechler et al. MEDICAL PHYSICS
- Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics,125Sn–177Lu is superior to90Y–177Lu in peptide receptor radiotherapy
- (2012) Stephan Walrand et al. PHYSICS IN MEDICINE AND BIOLOGY
- Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy
- (2012) Maria Larsson et al. EJNMMI Research
- Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
- (2012) A. Filice et al. Journal of Oncology
- Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts
- (2011) Stephan Walrand et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide
- (2011) Roberto Sghedoni et al. NUCLEAR MEDICINE COMMUNICATIONS
- 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
- (2010) Michael Garkavij et al. CANCER
- EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting
- (2010) M. Lassmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- An evaluation of R2 as an inadequate measure for nonlinear models in pharmacological and biochemical research: a Monte Carlo approach
- (2010) Andrej-Nikolai Spiess et al. BMC Pharmacology & Toxicology
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- (2009) Dik J Kwekkeboom et al. ENDOCRINE-RELATED CANCER
- Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
- (2009) Mattias Sandström et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies
- (2009) Bin He et al. MEDICAL PHYSICS
- Calculation of the biological effective dose for piecewise defined dose-rate fits
- (2009) Robert F. Hobbs et al. MEDICAL PHYSICS
- Comparing time activity curves using the Akaike information criterion
- (2009) Peter Kletting et al. PHYSICS IN MEDICINE AND BIOLOGY
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy
- (2008) B. W. Wessels et al. JOURNAL OF NUCLEAR MEDICINE
- Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry
- (2008) Sébastien Baechler et al. MEDICAL PHYSICS
- Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations
- (2008) Elisa Grassi et al. NUCLEAR MEDICINE COMMUNICATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started